Cargando…

1043. Activity of Mecillinam Against Enterobacterales Isolates Collected From Patients With Urinary Tract Infections (UTIs) in the USA During 2019

BACKGROUND: Mecillinam is a β-lactam antibiotic that exerts its antibacterial activity by binding to penicillin-binding protein 2. In the USA, intravenous (IV) mecillinam is in development for the treatment of complicated UTIs in the hospital setting and as step-down therapy transitioning from IV me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawser, Stephen, Morrissey, Ian, Henriksen, Anne Santerre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644386/ http://dx.doi.org/10.1093/ofid/ofab466.1237

Ejemplares similares

1617. Mecillinam susceptibility against Enterobacterales isolated from urinary tract infections from US patients in 2018
por: Hawser, Stephen, et al.
Publicado: (2020)

1433. Impact of 2019 US Food and Drug Administration (FDA) Guidance on Developing Drugs for Urinary Tract Infection (UTI) on the Perceived Efficacy of Antibiotics for the Treatment of Uncomplicated UTI (uUTI)
por: Henriksen, Anne Santerre, et al.
Publicado: (2021)

1428. Increased Consumption of Pivmecillinam in Primary Care for Uncomplicated Urinary Tract Infection (uUTI) Is Not Associated With Increased Resistance Rates
por: Larsen, Anders Rhod, et al.
Publicado: (2021)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam
por: Fuchs, Frieder, et al.
Publicado: (2021)

In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales
por: Plambeck, Lars, et al.
Publicado: (2022)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Reviving the role of mecillinam against extended spectrum beta-lactamase producing enterobacterales
por: Kaleem, Fatima, et al.
Publicado: (2022)

Urinary tract infection (UTI) and infection control in municipal nursing homes
por: Andersen, A-M, et al.
Publicado: (2011)

1945. Antibacterial activity of cefepime/enmetazobactam and comparator agents against U.S. Enterobacterales clinical isolates collected from 2019-2021
por: Belley, Adam, et al.
Publicado: (2023)

Retracted: In vivo mecillinam resistance in Escherichia coli after pivmecillinam treatment of a urinary tract infection
Publicado: (2019)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

1293. In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020
por: Hackel, Meredith, et al.
Publicado: (2021)

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales
por: Lodise, Thomas P, et al.
Publicado: (2021)

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER
por: Masarova, L., et al.
Publicado: (2022)

Frailty associated urinary tract infections (FaUTIs)
por: Kostakopoulos, Nikolaos A., et al.
Publicado: (2021)

P1043: EFFICACY AND SAFETY OF TRAMETINIB IN ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS AND ERDHEIM-CHESTER DISEASE
por: Latyshev, Vitalii, et al.
Publicado: (2023)

2826. Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing Enterobacterales and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)
por: Fernandez, Maria, et al.
Publicado: (2023)

Mecillinam – Reversion of Resistance and How to Test It
por: Frimodt-Moller, Niels
Publicado: (2017)

P04.61. Do infectious disease (ID) physicians use cranberry for prevention of urinary tract infections (UTI)?
por: Shere-Wolfe, K, et al.
Publicado: (2012)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count
por: Behzadi, Payam, et al.
Publicado: (2019)

1330. Development of a Pediatric Emergency Department (ED) Uropathogen Antibiogram and Empiric Urinary Tract Infection (UTI) Treatment Algorithm
por: Dass, Akshith M, et al.
Publicado: (2020)

1691. Pre- and Post-Hospitalization Resource Utilization and Costs Associated with Urinary Tract Infection (UTI) in both Commercial and Medicare Populations
por: Melnick, David, et al.
Publicado: (2020)

1425. Revisiting β-Lactams for Treatment of Uncomplicated Urinary Tract Infections: Evaluation of Twice-daily Cephalexin for Empiric Treatment of UTIs
por: Benning, Molly, et al.
Publicado: (2021)

High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli
por: Søraas, Arne, et al.
Publicado: (2014)

1419. High Prevalence of Fluoroquinolone-Resistant Urinary Tract Infection Among US Emergency Department Patients Diagnosed with UTI, 2018-2020
por: Faine, Brett, et al.
Publicado: (2021)

The role of toll-like receptors (TLRs) in urinary tract infections (UTIs)
por: Behzadi, Elham, et al.
Publicado: (2016)

Paper and thread as media for the frugal detection of urinary tract infections (UTIs)
por: Hasandka, Amrutha, et al.
Publicado: (2021)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

P198: Antimicrobial treatment for urinary tract infection (UTI) among patients having total hip (THA) or total knee arthroplasty (TKA)
por: Herwaldt, L, et al.
Publicado: (2013)

1684. Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis
por: Melnick, David, et al.
Publicado: (2020)

2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

42. INSPIRE-ASP UTI Trial: A 59 Hospital Cluster Randomized Evaluation of INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients with Urinary Tract Infection (UTI)
por: Gohil, Shruti K, et al.
Publicado: (2021)

Best practices in treatment of urinary tract infections (UTIs): “low-hanging fruit”
Publicado: (2019)

Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs
por: Josephs-Spaulding, Jonathan, et al.
Publicado: (2021)

1670. Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

1682. Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)
por: Mendes, Rodrigo E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_klusq9dbvf36km7h88ee5cth84